News Image

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Provided By GlobeNewswire

Last update: Nov 4, 2025

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business

Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million

Read more at globenewswire.com

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (12/19/2025, 8:00:01 PM)

After market: 9.55 +0.31 (+3.35%)

9.24

-0.73 (-7.32%)



Find more stocks in the Stock Screener

Follow ChartMill for more